Cat Lutz, PhD, MBA, Vice President of the JAX Rare Disease Translational Center, discusses rare disease research’s impact on understanding common diseases.
Developing therapeutics for rare diseases come with their own set of unique challenges and opportunities. Rare disease research is often distinctive and emphasizes urgency, individualized approaches, and accelerated regulatory procedures.
The rarity of patients with such conditions pose significant challenges in conducting traditional clinical trials, requiring a different approach. This may include n-of-1 studies, in which the treatment is tailored to each patient’s unique needs.
Lutz emphasizes that some patients may not live long enough for a treatment to go through the usual approval processes. Because of this, FDA accelerated pathways are utilized, allowing for quicker testing and implementation of potential treatments. This urgency propels researchers to explore cutting-edge technologies such as antisense oligonucleotides (ASOs) and gene editing.
The profound learning experiences derived from rare disease research are positioned as the catalysts for advancing genetic-based medicines. These lessons are expected to shape the mainstream adoption of technologies like ASOs and gene editing. The future may include gene-based and genetic-based medicines becoming commonplace.
For more information on rare diseases, visit https://checkrare.com/
